The local medical landscape is abuzz with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for addressing obesity. This treatment https://bookmarkprobe.com/story22047224/retatrutide-australia-a-new-prospect-for-obesity-treatment